AR090972A1 - Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf - Google Patents

Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf

Info

Publication number
AR090972A1
AR090972A1 ARP130101566A AR090972A1 AR 090972 A1 AR090972 A1 AR 090972A1 AR P130101566 A ARP130101566 A AR P130101566A AR 090972 A1 AR090972 A1 AR 090972A1
Authority
AR
Argentina
Prior art keywords
weeks
vegf
patient
vegf therapy
resistant patients
Prior art date
Application number
Other languages
English (en)
Inventor
C Hohman Thomas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR090972A1 publication Critical patent/AR090972A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para el tratamiento de un paciente que tiene una afección ocular, por ejemplo, degeneración macular relacionada con la edad o edema macular diabético, a través de la administración de una proteína de unión recombinante que comprende un dominio de repetición de anquirina. Se puede administrar la composición entre cada 8 semanas y cada 16 semanas. El paciente que se está tratando puede ser resistente a las terapias anti-VEGF actuales. Reivindicación 1: Uso de una proteína de unión recombinante que comprende un dominio de repetición de anquirina, en donde el dominio de anquirina se une a VEGF-Axxx con una Kd inferior a 10⁹ M, caracterizado porque es para la preparación de un medicamento útil para inhibir la unión entre VEGF-Axxx y VEGFR-2 en un paciente que necesite dicha inhibición, administrándose con una frecuencia de entre 8 semanas y 16 semanas una dosis de entre 1 mg y 4 mg.
ARP130101566 2012-05-07 2013-05-07 Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf AR090972A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643878P 2012-05-07 2012-05-07
US201261728017P 2012-11-19 2012-11-19
US201261731238P 2012-11-29 2012-11-29

Publications (1)

Publication Number Publication Date
AR090972A1 true AR090972A1 (es) 2014-12-17

Family

ID=48446670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101566 AR090972A1 (es) 2012-05-07 2013-05-07 Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf

Country Status (10)

Country Link
US (3) US10568934B2 (es)
EP (2) EP3646880A1 (es)
AR (1) AR090972A1 (es)
DK (1) DK2846836T3 (es)
ES (1) ES2753135T3 (es)
HU (1) HUE046134T2 (es)
PL (1) PL2846836T3 (es)
PT (1) PT2846836T (es)
TW (1) TW201350128A (es)
WO (1) WO2013169614A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
AU2014218318B2 (en) * 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
DK3065761T3 (da) * 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX2017012506A (es) 2015-03-31 2018-06-27 Ildong Pharm Co Ltd Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
AU2017286673B2 (en) * 2016-06-16 2021-06-24 Adverum Biotechnologies, Inc. Treatment of AMD using AAV2 variant with aflibercept
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US5932440A (en) 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
US5827692A (en) 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
CA2296508A1 (en) 1997-07-18 1999-01-28 Yale University Structure of the ankyrin binding domain of a alpha-na,k-atpase
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1544299T3 (da) 1999-06-08 2009-03-23 Regeneron Pharma VEGF-receptorkimærer til behandling af öjensygdomme, kendetegnet ved vaskulær permeabilitet
US20020042094A1 (en) 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
WO2001061005A2 (en) 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
AU2001278859A1 (en) 2000-06-29 2002-01-14 University Of Florida Ubiquitin ligase
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US20060121045A1 (en) 2004-11-08 2006-06-08 Brent Iverson Antibody fragments for protection from pathogen infection and methods of use thereof
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
EP2263088A2 (en) 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
KR101782790B1 (ko) 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
DK3065761T3 (da) 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin

Also Published As

Publication number Publication date
HUE046134T2 (hu) 2020-02-28
TW201350128A (zh) 2013-12-16
EP3646880A1 (en) 2020-05-06
PL2846836T3 (pl) 2020-01-31
US20130296238A1 (en) 2013-11-07
US20200405808A1 (en) 2020-12-31
US10568934B2 (en) 2020-02-25
WO2013169614A1 (en) 2013-11-14
US20220096596A1 (en) 2022-03-31
EP2846836A1 (en) 2015-03-18
EP2846836B1 (en) 2019-08-14
ES2753135T3 (es) 2020-04-07
DK2846836T3 (da) 2019-11-11
PT2846836T (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
PH12020500555A1 (en) Esketamine for the treatment of depression
EA201490254A1 (ru) Комбинированное лечение гепатита с
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2019012884A (es) Terapia de combinacion.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Legal Events

Date Code Title Description
FB Suspension of granting procedure